Eris Lifesciences Limited — Q3 FY25 earnings call

Call held 4 Feb 2025

Management summary

ERIS delivered a strong Q3 FY25 characterized by high consolidated growth driven by acquisitions and steady 12% organic growth in its core domestic business. The company is significantly ahead of its deleveraging targets, which, combined with manufacturing insourcing and new product launches like GLP-1s, is expected to trigger a massive 50%+ EPS growth in FY26. While gross margins face pressure from a changing business mix, aggressive cost synergies and insourcing are offsetting the impact at the EBITDA level.

Highlights

  • Consolidated operating revenue grew 50% YoY to ₹727 crores in Q3 FY25.

  • Consolidated EBITDA increased 43% YoY to ₹250 crores, with a 9-month EBITDA of ₹765 crores.

  • Flagship Domestic Branded Formulations (DBF) business delivered 12% organic growth in Q3.

  • Net debt reduction is ₹500 crores ahead of schedule, projected at ₹2,100 crores by end-FY25.

  • Management projects an EPS inflection point in FY26 with estimated growth of more than 50%.

  • Bhopal facility insourcing of insulin is expected to drive a 1,200 bps gross margin expansion for that segment.

  • Targeting first-wave launch of Semaglutide (GLP-1) in India by Q1 CY26.

  • Swiss Parenterals 9-month revenue reached ₹232 crores, on track for ₹330 crores FY25 guidance.

Key financials

  1. Consolidated Revenue ₹727 Cr +50%YoY
  2. Consolidated EBITDA ₹250 Cr +43%YoY
  3. DBF Revenue ₹635 Cr +35%YoY
  4. DBF EBITDA Margin 39%
  5. Net Debt ₹2,100 Cr
  6. Book Tax Rate 25.2%

What they filed

Q1 FY27: revenue down 23.3%, net profit down 52.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue437 400 405 579 650 +49%315 −21%277 −32%444 −23%
EBITDA143 100 121 216 297 +108%77 −23%22 −82%120 −44%
Net profit28 2 30 100 150 +436%3 +50%-9 −130%48 −52%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic Branded Formulations (DBF)
    ₹635 Cr Revenue₹230 Cr EBITDA12% Organic Growth
  • Swiss Parenterals (RoW Injectables)
    ₹232 Cr 9M Revenue₹76 Cr 9M EBITDA

Guidance & targets

Profitability

  • EPS Growth Profitability · FY26 · High confidence >50%
    Now when we look at FY26, we are seeing an inflection point with an EPS growth estimated of more than 50% in FY26 due to three factors playing out.

    — V. Krishnakumar, COO

Debt

  • Net Debt Debt · FY25 · High confidence ₹2,100 crores

    Previously ₹2,600 crores → ₹2,100 crores

    We told you that by the end of this financial year, we will have a net debt of Rs. 2,600 crores, and we are currently looking at being at Rs. 2,100 crores. This represents Rs. 500 crores ahead of target.

    — V. Krishnakumar, COO

  • Debt-to-EBITDA Ratio Debt · mid-FY26 · High confidence 1.5x

    From 4x today

    By mid of the next financial year, we will get to our target number of 1.5x debt-to-EBITDA since we are looking at a net debt of Rs. 1,750 crores by the end of September'25.

    — V. Krishnakumar, COO

Revenue

  • Swiss Parenterals Revenue Revenue · FY25 · High confidence ₹330 crores
    this business is on track to deliver its FY25 guidance of Rs. 330 crores.

    — V. Krishnakumar, COO

Margin

  • Insulin Gross Margin Margin · by October 2025 · Medium confidence 72%

    From 60% today

    Insulin at this point of time would be more like a 60% gross margin... we expect this to be at around 72%. So, we expect 1,200 basis point increase in the gross margins.

    — Amit Bakshi, CMD

Other

  • In-house Manufacturing Proportion Other · next 2-3 years · Medium confidence 80%

    From 60s today

    80% in-house. We are aiming for 80% in-house.

    — Amit Bakshi, CMD

Risks & concerns

  • Insourcing Delays at Bhopal Facility

    medium

    Operationalizing insulin vials shifted from Q4 FY25 to Q1 FY26 due to licensing and biotech validation complexities.

    Management acknowledged

  • Gross Margin Compression

    medium

    Consolidated gross margins fell 600 bps YoY due to the lower-margin Biocon and Swiss Parenterals business mix.

    Both acknowledged

  • Regulatory Inspections

    low

    Brazilian ANVISA inspection scheduled for May; critical for kickstarting OSD exports in FY26.

    Management acknowledged

Areas of evasion (2)

  • Specific pricing for upcoming GLP-1 products
  • Detailed breakdown of historical sales for specific acquired brands (Oaknet, etc.) as they are now fully integrated.

Q&A highlights

2 direct
Insulin Market Shortages Direct
Those shortages are giving us and every other player actually a chance to grow better... This is around a Rs. 600-800 crores market which I am talking about.

Reveals a significant near-term growth tailwind in the insulin segment due to supply issues from the market leader.

Asked by Kunal Randeria, Axis Capital

Semaglutide (GLP-1) Strategy Direct
It's a given fact actually, Harith, that the Bio piece is less expensive and more scalable... we are all aiming for the 1st quarter of the calendar year of next year, 26.

Clarifies Eris's dual approach (synthetic for launch, recombinant for long-term cost leadership) in the high-potential GLP-1 market.

Asked by Harith Ahamed, Avendus Spark

Gross Debt Disclosure Partial
No, Bharat Bhai, there is nothing... We will tell the gross. Just give us some time... It takes two minutes.

Highlights analyst concern over transparency regarding gross debt vs. net debt, though management committed to providing the numbers.

Asked by Bharat Shah, ASK Investment Managers

2 min read 5 chapters

Detailed narrative

Debt Deleveraging and EPS Inflection Point

Eris is executing a rapid deleveraging strategy, expecting to end FY25 with a net debt of ₹2,100 crores, which is ₹500 crores better than previous guidance. This aggressive repayment, combined with organic growth and margin improvements in acquired businesses, is set to drive a massive EPS inflection point in FY26. Management estimates EPS growth will exceed 50% next year as interest expenses fall and the effective tax rate begins to decline from its current 25% peak.

Strategic Entry into the GLP-1 Market

The company is positioning itself as a leader in the Indian GLP-1 (Semaglutide) space, targeting a launch in Q1 CY26. Management aspires for the market to reach 1 million patients with a potential first-year revenue opportunity of ₹2,500 to ₹3,000 crores for the industry. Eris plans to use its Swiss Parenterals facility for synthetic peptide manufacturing initially, while transitioning to recombinant Semaglutide for long-term cost scalability.

Manufacturing Insourcing and Margin Expansion

A key driver for future profitability is the insourcing of insulin production to the Bhopal facility. While there have been minor delays, vial production is expected to start in Q1 FY26, followed by cartridges in H2 FY26. This shift is projected to expand gross margins for the insulin business by 1,200 basis points, moving from approximately 60% to 72%.

Integration and Performance of Acquisitions

The Biocon and Swiss Parenterals acquisitions have significantly altered the company's business mix, leading to a 600 bps drop in consolidated gross margins. However, management has successfully offset this with a 436 bps reduction in the fixed expense ratio through aggressive integration synergies. The Biocon business, in particular, is viewed as a strategic gateway into complex biotech products.

Domestic Branded Formulations Organic Momentum

The core DBF business delivered 12% organic growth in Q3, driven by new product launches and price increases. Management expressed that while 12% is a solid baseline, they aspire for 14-15% growth. The pipeline remains robust with three new Fixed Dose Combinations (FDCs) in the SGLT2 and DPP4 space slated for Q4 launch, alongside the scaling of Liraglutide which is already clocking ₹1 crore in monthly sales.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls